ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Cleveland, OH

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Cleveland, OH, USA:

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

immune response and demonstrate efficacy in patients with advanced triple-negative breast cancer.This study will ...

Active, not recruiting
Triple-negative Breast Cancer
Biological: Pembrolizumab
Biological: AE37 Peptide vaccine

Phase 2

NuGenerex Immuno-Oncology

Cleveland, Ohio, United States and 5 other locations

This is a Phase 2, Multi-Cohort, Open-Label, Multi-Center Study. Cohort 1 will be a single-arm study of intratumoral tavokinogene telseplasmid (TAVO)...

Active, not recruiting
Triple Negative Breast Cancer
Biological: Pembrolizumab
Device: Immunopulse

Phase 2

OncoSec Medical

Cleveland, Ohio, United States and 13 other locations

Locations recently updated

with stage I to III TNBC with residual invasive disease in the breast and/or axillary lymph nodes at surgical resection following neoadjuvan...

Enrolling
Breast Cancer
Drug: Pembrolizumab
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Cleveland, Ohio, United States and 359 other locations

(HCC), pancreatic ductal adenocarcinoma (PDAC), biliary tract cancers (BTC), esophageal squamous cell carcinoma (ESCC), triple negative...

Enrolling
Triple Negative Breast Cancer
Hormone Receptor+/Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer
Drug: ABBV-400

Phase 1

AbbVie
AbbVie

Cleveland, Ohio, United States and 35 other locations

besides treating your disease.Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed w...

Enrolling
Gastric Cancer
Triple Negative Breast Neoplasms
Drug: SGN-PDL1V
Drug: pembrolizumab

Phase 1

Seagen
Seagen

Cleveland, Ohio, United States and 22 other locations

The primary purpose of this study is to assess the safety and tolerability of AB598 when taken alone, and in combination with zimberelimab and standa...

Enrolling
Triple Negative Breast Cancer (TNBC)
Esophageal Cancer
Drug: AB598
Drug: Pemetrexed

Phase 1

Arcus Biosciences
Arcus Biosciences

Cleveland, Ohio, United States and 9 other locations

This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immuno...

Enrolling
Endometrial Cancer
Triple Negative Breast Cancer
Biological: NM32-2668

Phase 1

Numab Therapeutics

Cleveland, Ohio, United States and 4 other locations

This study is an an open-label Phase I trial of VT1021 in patients with advanced solid tumors. Patients must have recurrent or advanced cancer...

Active, not recruiting
Solid Tumor
Drug: VT1021

Phase 1

Vigeo Therapeutics

Cleveland, Ohio, United States and 11 other locations

The purpose of the trial is to evaluate the safety of acasunlimab (also known as GEN1046) as monotherapy and in combination therapies in patients wit...

Active, not recruiting
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort)

Phase 1, Phase 2

Genmab
Genmab

Cleveland, Ohio, United States and 56 other locations

The clinical study will assess the safety and tolerability of escalating intratumoral doses of mRNA-2752 in participants with relapsed/refractory sol...

Active, not recruiting
Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma
Biological: Durvalumab
Biological: mRNA-2752

Phase 1

Moderna
Moderna

Cleveland, Ohio, United States and 23 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems